Regeneron Pharmaceuticals
REGN
$14.34 (-1.48%)
1D
1W
3M
1Y
5Y
ALL
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Reuters • 10 hours ago • REGN
Regeneron's experimental gene therapy improves hearing in one patient
GlobeNewsWire • 10 hours ago • REGN
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
GlobeNewsWire • 2 days ago • REGN
Regeneron Announces Investor Conference Presentations
InvestorPlace • 4 days ago • REGN
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
InvestorPlace • 5 days ago • REGN
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.
